Time To Step-Up The Fight Against Nafld
Xiao-Jing Zhang,Zhi-Gang She,Hongliang Li
DOI: https://doi.org/10.1002/hep.29845
IF: 17.298
2018-01-01
Hepatology
Abstract:Over the past century, disease spectrums have undergone a world-wide epidemiological transition. Whereas many once-fatal infectious diseases (e.g., malaria, smallpox, and polio) have been eradicated in most countries benefiting from medical advances and new therapeutic developments, the incidence of metabolic disorders have sharply increased with the remarkable prevalence of overnutrition, and this sharp increase is threatening modern life. One apparent contributor to the epidemiological shift is the change of liver disease spectrum. The success of vaccines or therapeutic approaches make it possible to effectively cure or control the progression of chronic hepatitis B and C, which were the leading cause of cirrhosis worldwide; there has, however, been a tremendous increase in the prevalence of nonalcoholic fatty liver disease (NAFLD), which has become the leading cause of chronic liver disease afflicting more than 1 billion people worldwide. Most recently, prominent journals, including New England Journal of Medicine, Nature, Nature Reviews, Nature Medicine, Gastroenterology, and HEPATOLOGY, have published serial outlook and perspective articles calling for more attention to the management of NAFLD. NAFLD occurs in individuals with more than 5% hepatic steatosis (HS) that is not attributable to excess alcohol consumption or to other causes such as viral hepatitis or medications. Up to 30% of subjects with simple steatosis (nonalcoholic fatty liver; NAFL) progress to nonalcoholic steatohepatitis (NASH), as reflected by inflammation, hepatocyte ballooning, and, in its later stage, fibrosis. All fatty liver disease was, at one time, thought to be induced by excessive alcohol intake, and the term NASH was only coined in 1980 by Ludwig et al. at the Mayo Clinic. This report failed to attract sufficient attention at that time, and the concept of “NASH as a benign condition” endured until both clinical and epidemiological studies confirmed that NASH can be progressive and lead to liver-related morbidity and mortality after 10 years later. Up to 20% of NASH patients may further progress to cirrhosis, resulting in a markedly increased risk for hepatocellular carcinoma (HCC) and liver failure. Notably, NASH is correlated with a 10-fold increased risk of cirrhosis and HCC occurrence and contributes to a doubling of cardiovascular disease events. Moreover, NAFLD-related cirrhosis is currently the most rapidly increasing cause and second among indications for liver transplantation of adults in United States. Now, more than ever, NAFLD has become a significant clinical and economic burden, and cutting-edge research is urgently needed to discover effective therapies for NAFLD. The prevalence of NAFLD is still on the rise and, more alarmingly, the burden of NAFLD may, in fact, be much higher than is appreciated attributed to lack of recognition of the condition in broader medical community, as well as challenges in diagnosing this condition. Liver biopsy and blood aminotransferase levels are the most commonly applied diagnostic procedures for NAFLD, and biopsy-based pathology remains the only reliable standard to diagnose NASH. Abbreviations: HCC, hepatocellular carcinoma; HS, hepatic steatosis; HSCs, hepatic stellate cells; IR, insulin resistance; MetS, metabolic syndrome; MetS-predisposed, predisposed to metabolic syndrome; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis.